P21 10mg

P21 is the unmodified CNTF-derived peptide. P21-Adamantane has an adamantane group attached that increases lipophilicity and is expected to improve blood-brain barrier penetration for systemic delivery. For cell culture or ICV injection research, unmodified P21 is appropriate. For systemic injection studies where CNS penetration is a concern, P21-Adamantane is generally preferred. Both activate the same CNTFRalpha signaling pathway -- the difference is in pharmacokinetics and delivery efficiency, not mechanism.

P21 has been studied primarily in aged rodent models of cognitive decline. Research by Bolognesi and colleagues showed that P21 administration in aged rats stimulated hippocampal neurogenesis (measured by doublecortin-positive cell counts) and improved performance in spatial memory tasks compared to controls. The hypothesis is that restoring neurogenesis through CNTF pathway activation partially reverses age-related hippocampal neurogenic decline and the associated memory deficits. Human data is not available -- this is preclinical research.

P21 and CNTF share activity at CNTFRalpha but are not identical in their receptor complex signaling. Full CNTF signals through a tripartite receptor complex (CNTFRalpha + LIF receptor beta + gp130), with downstream JAK/STAT3 and MAPK activation. P21 is a partial agonist derived from the CNTFRalpha binding interface and may not fully recapitulate the complete CNTF signaling complex. In practice, P21's neurogenic and neuroprotective effects in rodent models suggest meaningful biological activity, but the receptor pharmacology may differ from full CNTF in ways that matter for certain research contexts.